Mitoxantrone
"Mitoxantrone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracenedione-derived antineoplastic agent.
Descriptor ID |
D008942
|
MeSH Number(s) |
D02.455.426.559.847.117.159.500 D02.806.100.500 D04.615.117.159.500
|
Concept/Terms |
Mitroxone- Mitroxone
- Columbia Brand of Mitoxantrone Hydrochloride
Pralifan- Pralifan
- Inibsa Brand of Mitoxantrone Hydrochloride
Novantrone- Novantrone
- Amgen Brand of Mitoxantrone Hydrochloride
- Wyeth Brand of Mitoxantrone Hydrochloride
- Novantron
- Ralenova
- AHP Brand of Mitoxantrone Hydrochloride
- Lederle Brand of Mitoxantrone Hydrochloride
Onkotrone- Onkotrone
- Baxter Oncology Brand of Mitoxantrone Hydrochloride
- ASTA Medica Brand of Mitoxantrone Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Mitoxantrone".
Below are MeSH descriptors whose meaning is more specific than "Mitoxantrone".
This graph shows the total number of publications written about "Mitoxantrone" by people in this website by year, and whether "Mitoxantrone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 1 | 1 | 2001 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitoxantrone" by people in Profiles.
-
Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
-
Enschede SH, Porter C, Venugopal P, Gregory SA. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
-
Preisler HD, Venugopal P, Gregory SA, Adler S, Gezer S, Hsu WT, Manson S, Larson A, Jajeh A, Slvinick D, Galvez A. High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leuk Lymphoma. 2001 Apr; 41(3-4):333-6.
-
Preisler HD, Venugopal P, Gregory SA, Hsu W, Loew J, Adler S, Gezer S, Creech S, Galvez A, Slivnick D, Andric T, Larson RA, Jajeh A. Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). Leuk Res. 2000 Aug; 24(8):671-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|